The total return over the past 12 months is -21.14% vs. +16.94% for the S&P 500. So far it's up +19.89% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (21.14%) | +205.27% | +27.38% | N/A | N/A | N/A |
| Total Return CAGR | (21.14%) | +205.27% | +27.38% | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Monopar Therapeutics Inc. (MNPR)
| Year | Start price | End price | MNPR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $65.30 | $78.29 | +19.89% | +14.51% | +5.38% |
| 2025 | $22.00 | $65.30 | +196.82% | +17.72% | +179.10% |
| 2024 | $1.70 | $22.00 | +1194.12% | +24.89% | +1169.23% |
| 2023 | $11.85 | $1.70 | (85.65%) | +26.19% | (111.84%) |
| 2022 | $16.05 | $11.85 | (26.17%) | (18.17%) | (8.00%) |
| 2021 | $30.60 | $16.05 | (47.55%) | +28.74% | (76.29%) |
| 2020 | $83.00 | $30.60 | (63.13%) | +18.37% | (81.50%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
